Skip to main content
. 2014 Oct 1;18(10):615–624. doi: 10.1089/omi.2014.0042

FIG. 1.

FIG. 1.

Detection of the USP9Y-TTTY15 fusion transcript in prostate cancer and adjacent nonmalignant prostate tissue. (A) Examples of the RT-PCR products of the USP9Y-TTTY15 fusion transcript at 232 bp in prostate cancer (lanes 1–5) and case-matched adjacent normal tissue (lanes 6–10) samples along with a negative control without input cDNA template (lane 11). Marker: 1 Kb plus (Life Technology) DNA size marker. (B) Schematic presentation of the alignment of TTTY15 and USP9Y on the Y chromosome and the fusion transcripts based on the sequencing data of the fusion at the end of USP9Y exon 3 and the beginning of TTTY15 exon 3. The bottom panel is a representative image of the fusion sequence from a clinical sample. The position of the nucleotide fusion site is indicated by the black arrows.